Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verekitug in moderate-to-severe COPD
NCT06981078Phase 2Active, not recruiting
- Sponsor
- Upstream Bio
- Start
- Jul 2025
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of vereckitug in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Upstream Bio. Primary endpoint: Annualized rate of moderate or severe COPD exacerbation events at 108 weeks. Started Jul 2025; status: active, not recruiting.
02
Drugs
vereckitug
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06981078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981078.